Related Experiment Video
Updated: Jul 19, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Minimal-model estimates of insulin sensitivity are insensitive to errors in glucose effectiveness
C McDonald1, A Dunaif, D T Finegood
1Diabetes Research Laboratory, School of Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada.
The Journal of Clinical Endocrinology and Metabolism
|July 21, 2000
Summary
The minimal-model accurately estimates insulin sensitivity (S(I)) despite potential overestimations in glucose effectiveness (S(G)). Adjusting S(G) did not significantly impact S(I) calculations in this study.
Area of Science:
- Metabolic research
- Physiological modeling
- Endocrinology
Background:
- The minimal-model estimates insulin sensitivity (S(I)) and glucose effectiveness (S(G)) from glucose and insulin dynamics.
- Previous work indicated minimal-model overestimates S(G) in individuals with normal insulin secretion.
Purpose of the Study:
- To investigate if overestimation of S(G) affects the estimation of S(I) using the minimal-model.
- To determine the independence of S(I) estimation from S(G) accuracy.
Main Methods:
- Analysis of 56 glucose tolerance tests from women of varying weight and PCOS status.
- Constraining the glucose effectiveness (S(G)) parameter in the minimal-model to lower values.
- Examining the impact on the insulin sensitivity index (S(I)) estimation.
Main Results:
- Constraining S(G) led to significant increases in other model parameters (P2, P3).
- Despite substantial S(G) constraint (down to 40% of unconstrained value), S(I) decreased by only 3%.
- Insulin sensitivity index (S(I)) remained largely unaffected by S(G) value adjustments.
Conclusions:
- Minimal-model-derived insulin sensitivity (S(I)) estimation is robust and independent of potential errors in glucose effectiveness (S(G)) calculations.
- The findings support the reliability of S(I) derived from the minimal-model, even with imperfect S(G) values.
More Related Videos
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

